NSCLC
iOnctura expands clinical trial programme for NSCLC
July 9, 2024Research and Development NSCLC, Oncology, clinical trial, iOnctura, lung cancer
iOnctura has announced the expansion of its clinical trial programme for its lead pipeline asset, roginolisib.
AstraZeneca shares results from phase 3 TROPION-Lung01 trial
May 28, 2024Medical Communications AstraZeneca, Daiichi Sankyo, NSCLC, Oncology, clinical trial, datopotamab deruxtecan
AstraZeneca has announced results from the phase 3 TROPION-Lung01 trial of AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan (Dato-DXd). The survival …
FDA approves J&J’s Rybrevant with chemotherapy for NSCLC treatment
March 4, 2024Medical Communications FDA, Johnson & Johnson, NSCLC, Oncology, Rybrevant
Johnson & Johnson have announced that the US Food and Drug Administration (FDA) has approved Rybrevant (amibantamab-vmjw) following a priority …
Verastem Oncology gains Fast Track Designation for combination NSCLC treatment
January 19, 2024Medical Communications Cancer, FDA, NSCLC, Oncology, Verastem Oncology
Verastem Oncology has announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation to the company’s …
Merck and Moderna initiate phase 3 study of NSCLC treatment
December 13, 2023Medical Communications Merck, Moderna, NSCLC, Oncology, clinical trial
Merck (known as MSD outside of the US and Canada) and Moderna have announced the initiation of the phase 3 …
AstraZeneca and Daiichi Sankyo’s Enhertu approved in EU for treatment of HER2-mutant NSCLC
October 23, 2023Research and Development AstraZeneca, Daiichi Sankyo, Enhertu, NSCLC, Oncology
AstraZeneca and Daiichi Sankyo have announced that Enhertu (trastuzumab deruxtecan) has been approved in the EU as a monotherapy for …
Kura Oncology shares preclinical data for NSCLC treatment
September 29, 2023Medical Communications Kura Oncology, NSCLC, Oncology, oncology
Kura Oncology has shared positive preclinical data which supports the development of its next-generation farnesyl transferase inhibitor (FTI) KO-2806 in …
AstraZeneca and Daiichi Sankyo share positive results from DESTINY-Lung02 phase 2 trial
September 11, 2023Medical Communications AstraZeneca, Daiichi Sankyo, Enhertu, NSCLC, Oncology, clinical trial
AstraZeneca and Daiichi Sankyo have announced results from the primary analysis of the DESTINY-Lung02 phase 2 trial, which showed Enhertu’s …
Genentech shares phase 3 results for ALK-positive early-stage lung cancer treatment
September 1, 2023Research and Development Genentech, NSCLC, Oncology, clinical trials, lung cancer
Roche’s Genentech has announced that the phase 3 ALINA trial assessing Alecensa, compared with platinum-based chemotherapy for the treatment of …
Daiichi Sankyo’s Enhertu approved in Japan as treatment for metastatic NSCLC
August 23, 2023Medical Communications Daiichi Sankyo, Enhertu, Japan's MHLW, NSCLC, Oncology, trastuzumab deruxtecan
Daiichi Sankyo has announced that Enhertu (trastuzumab deruxtecan) has been approved in Japan for the treatment of adult patients with …
AstraZeneca shares results from phase 3 trial of datopotamab deruxtecan for NSCLC
July 3, 2023Medical Communications AstraZeneca, NSCLC, Oncology, clinical trial, datopotamab deruxtecan
AstraZeneca has announced results from its TROPION-Lung01 phase 3 trial for its TROP2-directed antibody drug conjugate, developed in collaboration with …
BioInvent receives Investigational New Drug approval for monoclonal antibody BI-1910
June 2, 2023Research and Development BioInvent, NSCLC, Oncology, monoclonal antibody
Swedish clinical stage biotech company BioInvent has announced that it has received Investigational New Drug (IND) approval for its monoclonal …
Bristol Myers Squibb’s NDA accepted by FDA
May 31, 2023Medical Communications FDA, NDA, NSCLC, Oncology, bristol myers squibb
Global pharmaceutical company Bristol Myers Squibb (BMS) has announced that its New Drug Application (NDA) has been accepted by the …
New targeted lung cancer treatment coming to UK under MHRA scheme
July 15, 2021MHRA, NSCLC, UK, brexit
The MHRA has issued an Early Access to Medicines Scheme (EAMS) positive scientific opinion for tepotinib, for the treatment of …
Sanofi’s NSCLC drug gains EC approval
June 25, 2021Medical Communications EC, EU, NSCLC, Sanofi
The European Commission (EC) has approved Sanofi and Regeneron’s PD-1 inhibitor, Libtayo (cemiplimab), for the first-line treatment of adults with …
Latest content
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
Tridem begins phase Ib trial of Parkinson’s disease vaccine
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
